Newsroom

BIOPACT’S MGMR® DRUG DELIVERY TECHNOLOGY SUCCEEDS IN MITIGATING SIDE EFFECTS OF DOXORUBICIN WHILE RETAINING ANTI-CANCER EFFICACY IN LYMPHOMA AND METASTASIS MOUSE MODELS

Austin, TX (June 13, 2017) BioPact’s nanodelivery technology produced in vivo evidence that the carbon nanotube-based drug delivery system, Medical-Grade MOLECULAR REBAR® (MGMR®), successfully treated two forms of cancer while reducing the side effects of the API in this study, Doxorubicin. The studies were conducted at Charles River Laboratories and utilized two orthotopic cancer […]

By |June 13th, 2017|News|0 Comments

BIOPACT’S CO-FOUNDER RESUMES ROLE AS CHIEF EXECUTIVE OFFICER

Austin, TX (May 9th, 2017) BioPact’s co-founder, Kent Phelps, has resumed his role as CEO effective immediately. After 20 years of practicing law, Kent launched BioPact in 2014 with co-founder and lead investor Randy Kinsel.  BioPact was later established as a joint venture with the inventors of Molecular Rebar®, Kurt Swogger and Dr. […]

By |May 11th, 2017|News|0 Comments

BIOPACT’S MGMR® DRUG DELIVERY TECHNOLOGY SUCCEEDS IN TRANSPORTING CELL IMPERMEABLE PEPTIDES ACROSS CELL MEMBRANE TRIGGERING 100% CANCER CELL DEATH

Austin, TX (March 9, 2017) BioPact’s nanodelivery technology, MGMR®, demonstrated highly efficacious intracellular delivery of KLAKLAK, a pro-apoptotic peptide known to be cell membrane impermeable. When loaded on MGMR, KLAKLAK crossed the cell membrane of LNCaP human prostate cancer cells, triggering apoptosis in 100% of the cells in repeated studies.

KLAKLAK is a 1.5kD peptide […]

By |March 10th, 2017|News|0 Comments

BIOPACT ANNOUNCES MAXIMUM TOLERATED DOSE STUDY RESULTS FOR ITS MEDICAL GRADE MOLECULAR REBAR (MGMR®) NANOTECHNOLOGY

Cambridge, MA- (May 10, 2016) BioPact announced tolerability assessment data of its MGMR® (Medical Grade Molecular Rebar) nanotechnology. Study results indicated the maximum tolerated dose of MGMR is 180% higher than the therapeutically significant dose that was used in its previous successful safety study. Secondary endpoints indicated that multiple daily dosing was deemed well […]

By |May 11th, 2016|News|0 Comments

BIOPACT SEEKS DIRECTOR OF RESEARCH AND DEVELOPMENT

OUR COMPANY:

BioPact is a nano-technology development company based in Cambridge, MA. BioPact’s Medical Grade Molecular Rebar (MGMR®) is a unique composition of matter derived from carbon nanotubes. MGMR® is made up of discrete (individualized), medical grade, open-ended, length controlled, and surface functionalized carbon nanotubes. The unique physical and chemical properties of these tubes overcome […]

By |February 5th, 2016|News|0 Comments

BIOPACT RECEIVES 2016 TECHNOLOGY INNOVATION AWARD FOR ITS MGMR® NANO-DRUG DELIVERY TECHNOLOGY

Cambridge, MA—(January 28, 2016) BioPact is the 2016 recipient of the Drug Delivery Partnerships Technology Innovation Award. The award celebrates game-changing technological innovation in drug delivery over the past year. For 20 years, Drug Delivery Partnerships (DDP) has been the world’s largest drug delivery meeting to accelerate drugs to market and lengthen lifecycles by finding new partners, new drug delivery technologies, and new formulation development strategies.

DDPBioPact’s Chief Executive Officer, Joe Dillon, Ph.D., MBA, accepted the award on behalf of the company. Dr. Dillon said, “We at BioPact wish to thank Drug Delivery Partnerships for selecting our ground-breaking nano-drug delivery technology, MGMR®, for this award out of all of the other deserving nominees. Our unique and proprietary composition of discrete carbon nanotubes has many important medical applications in areas of high unmet patient need. And we look forward to working with our partners to develop innovative therapies.”

Lainie Mulvanny, BioPact’s Vice President of Business Development, was also in attendance at this year’s meeting. She said, “Bringing this disruptive technology to DDP has changed the drug delivery landscape. We look forward to future endeavors with new partners.”

About BioPact

BioPact is a nanotechnology development company based in Cambridge, MA. BioPact’s Medical Grade Molecular Rebar (MGMR®), is a unique composition of matter derived from carbon nanotubes. MGMR® are discrete (individual), length controlled, surface functionalized, open-ended, medical grade carbon nanotubes. The unique physical and chemical properties of these tubes overcome the limitations of traditional dirty, tangled carbon nanotube bundles. BioPact is focused on developing and partnering MGMR® for use in drug delivery, orthotics, regenerative medicine, devices, diagnostics, bio-sensors, material optimization and a number of other medical applications addressing substantial unmet needs in patient care. Please visit us at www.bio-pact.com

Media Contact

Lainie Mulvanny

LainieM@bio-pact.com

By |January 29th, 2016|News|0 Comments

BIOPACT ANNOUNCES APPOINTMENT OF JOE DILLON AS CHIEF EXECUTIVE OFFICER

Cambridge, MA--(November 30, 2015) – BioPact Ventures, LLC today announced the appointment of Joe Dillon, Ph.D., as Chief Executive Officer, effective immediately. Dr. Dillon joined BioPact in June 2015 as its executive advisor and will lead the company as it advances its MGMR® medical technology. He replaces Kent Phelps, co-founder of BioPact. Mr. Phelps will continue to be involved with Bio-Pact as a consultant and as the Chief Legal Counsel.

“BioPact continues to develop and advance its MGMR®, a unique and proprietary composition of discrete carbon nanotubes with many important medical applications. We are excited about bringing Joe in to take the company to the next level," said Kurt Swogger, Manager of BioPact Ventures, LLC. "We are grateful to Kent for his leadership and success in leading the establishment of BioPact and selection of its first commercial target that of controlled release of pharmaceuticals. Joe will take it the next steps in securing the needed partners to develop specific applications that will bring MGMR® to market using his many years of experience and knowledge”.

JDillonDr. Dillon was most recently President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 20 years of experience. He has extensive experience in global pharmaceutical and biotechnology business strategy and planning, product development, operations and strategic transactions. Prior to forming SynerPhysics and Dillon Capital Strategies, Dr. Dillon held senior positions in two pharmaceutical management consulting firms, most significantly was as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. Dr. Dillon holds a Ph.D. in Metaphysics, an M.B.A. in International Finance and a bachelors in Finance.
About BioPact:

BioPact is a medical nano-technology development company based in Cambridge, MA. Bio-Pact’s Medical Grade Molecular Rebar (MGMR®), is a unique composition of matter derived from carbon nanotubes, which are discrete (individual), open-ended, length controlled and surface functionalized. The unique physical and chemical properties of these tubes overcome the limitations of traditional carbon nanotubes. BioPact is focused on developing and partnering MGMR® for use in drug delivery, orthotics, regenerative medicine, devices, diagnostics, bio-sensors, material optimization and a number of other medical applications addressing substantial unmet needs in patient care. Please visit us at www.bio-pact.com

Media Contact:

Lainie Mulvanny

lainiem@bio-pact.com

By |December 4th, 2015|News|0 Comments

CHEMISTRY&INDUSTRY • SEPTEMBER 2015

From Chemistry & Industry News, September 2015

C_I

‘THE ANNOUNCEMENT OF BENIGN, NON- TOXIC NANOTUBES IS SIGNIFICANT AND EXCITING'
Andrei Khlobystov director, University of Nottingham’s Nanotechnology & Nanoscience Centre

MEDICAL GRADE NANOTUBES
Cath O’Driscoll

After years of searching, researchers say they have come up with a scalable process to make ‘the world’s first medical grade carbon nanotube’.

Not only are the new Medical Grade Molecular Rebar (MGMR) nanotubes safe and non-toxic, according to researchers at Cambridge, MA-based company BioPact, which exhibited the technology at the ACS meeting in Boston in August 2015, but crucially they can also be made in quantities of several tonnes/ year– up to commercial-scale as needed.

‘Ever since they were discovered in 1991, people have spent billions trying to get a scalable technology to make discrete, clean, consistent batches of carbon nanotubes,’ said Herschel Watkins, lead scientist at BioPact. ‘Now we have solved that problem.’

Carbon nanotubes (CNTs) hold tremendous potential in medicine because of their high aspect ratio: their relatively long length and small width means they have an extremely high surface area that allows them to enter cells and cross the blood- brain barrier into the brain. To date, however, applications have been limited because of safety concerns.

Current manufacturing processes for CNTs leave behind traces of heavy and sometimes toxic metals such as cadmium, lead and alumina, which can leach out and poison the host, Watkins elaborated. They also frequently result in a ‘knotted amorphous mass’ of tubes, ranging from a few microns to tens of microns long, that have lost their needle-like shape and are associated with asbestos-like carcinogenicity problems seen in animal studies.

‘Getting the metals out has until now been an expensive and not really scalable process,’ Watkins said. ‘People have made short tubes without metals before but only at a small scale in laboratories, so to get a few mg would take a week or more. One reason we are so different is because our process is scalable.’

The new manufacturing process to make MGMR nanotubes was invented by a group of former-Dow Chemical company scientists who set up a separate, partner company to BioPact to develop the tube and explore other non-medical and energy-related applications.

Details of the process remain under wraps; however, Watkins notes that it results in consistent batches of clean, open-ended nanotubes all less than a single micron in length ready for targeted drug delivery applications.

‘The higher the aspect ratio, the more surface area relative to the smallest dimension but if the tubes are too long they can raise toxicity concerns,’ he said: ‘Tubes from 10–15nm across by 800–900nm long are the optimal dimension to create a safe high surface area particle while maintaining a narrow cross section.’

Unpublished studies in mice have shown that MGMR tubes are safe and free from side effects even at doses up to 3mg, Watkins notes – equivalent to a 12g dose in humans. Mice given one of the ‘best commercially available’ CNTs, in contrast, all died after the first dose, Watkins says, ‘whereas all our mice survived the entire experiment with no effects.’

Four R&D kits containing the MGMR tubes are now being made available for exploratory studies.

‘The announcement of biologically benign, non-toxic carbon nanotubes is significant and exciting,’ commented Andrei Khlobystov, director of the University of Nottingham’s Nanotechnology & Nanoscience Centre. ‘This opens up a huge potential avenue for nanotube applications in medicine, from cancer therapy, to transdermal drug delivery, to new treatments for neurodegenerative diseases. The sub-micrometre length of the BioPact nanotubes and their surface functionality compatible with biological systems must play roles as important as the nanotubes purity for minimising their toxicity.’

However, to harness the full potential of the MGMR tubes for drug delivery and other therapeutic applications, Khlobystov added that ‘the fundamental physical chemistry of drug molecules encapsulation and release needs to be fully explored and understood. The nanotube-molecule interactions are highly complex and unpredictable, and require careful spectroscopy and microscopy analysis at each stage, so I will be eagerly watching development of this new nanomaterial towards real-life applications.’

The process to make MGMR tubes will be ‘significantly less than for other methods to make clean CNTs,’ Watkins said; they will add very little to the overall cost of an approved drug.

By |October 14th, 2015|News|0 Comments

BIOPACT LAUNCHES R&D KITS IN PHILADELPHIA AT BIO CONFERENCE

BioPact
800-561-7087
Inquiries@Bio-Pact.com | bio-pact.com | Twitter | Facebook | YouTube

 

BioPact, a Cambridge based company, announced the launch of new research and development kits featuring their revolutionary nanomaterial. Their launch coincides with the largest gathering in biotech, the Bio International Conferencein Philadelphia, June 15-18. The BioPact team is exhibiting the new kits in the Massachusetts Pavilion […]

By |June 15th, 2015|News|0 Comments

BIOPACT CONGRATULATES WINNERS OF THE M2D2 NEW VENTURE COMPETITION

The winners of the UMass-sponsored New Venture medical device competition were announced yesterday, with PixelEXX taking the top prize – $35,000 in scientific development, consulting, and legal services. PixelEXX has invented a sub micron endoscopy camera. Other winners included Soft Robotics, Novopyxis, Micro-Leads, and Nido Surgical. BioPact congratulates these innovative companies and thanks M2D2 […]

By |May 17th, 2015|News|0 Comments